IASLC Lung Cancer Immunotherapy Meeting March 22-25, 2018

Transcription

1 IASLC Lung Cancer Immunotherapy Meeting March 22-25, 2018 Hotel: Meliã Castilla Calle del Poeta Joan Maragall, 43 Madrid, Spain Organizing Committee: Tony Mok, Roy Herbst, Luis Paz-Ares, David Carbone, Fred R. Hirsch, Giorgio V. Scagliotti, Federico Cappuzzo, Pia Hirsch, Murry Wynes Thursday, March 22, :00 6:00 p.m. Registration and Reception 6:00 6:30 p.m. Keynote Speaker I Laurence Zitvogel 6:30 6:45 p.m. Keynote Speaker II Lung Cancer Treatment Progress: Advocate Perspective Stefania Vallone 6:45 7:00 p.m. Tobacco and E-cigarette Induced Inflammation Peter Shields Friday, March 23, :30 9:30 a.m. Session I: Basic Immunology Chairs: Licia Rivoltini, TBD 8:00 8:20 a.m. Basic Immunological Principles Ignacio Melero 8:20 8:40 a.m. Immunologic Drug Development Daniel Tan 8:40 9:00 a.m. Discussion Licia Rivoltini 9:00 10:00 a.m. Session II: Animal Models Preclinical Studies and Phase I Studies Chairs: Ignacio Melero, Roy Herbst 9:00 9:15 a.m. Patient-Derived Tumor Models for Immunotherapy Development 9:15 9:30 a.m. Cytokine-Induced Killer Cells as Immunotherapy for Solid Tumors: Current Evidence and Perspectives 9:30 9:45 a.m. Phase I Studies with Novel Immunotherapeutics Miguel Sanmamed Dario Sangiolo Roy Herbst 9:45 10:00 a.m. Discussion Roy Herbst 10:00 10:15 a.m. Coffee Break

2 Friday, March 23, :15 a.m. Noon Session III: Immunodiagnostics Chairs: Keith Kerr, Elisabeth Brambilla 10:15 10:35 a.m. PD-L1 Fred R. Hirsch 10:35 10:55 a.m. Other IHC Markers Fernando López-Ríos 10:55 11:15 a.m. Mutation Burden (Tumor/Plasma) David Carbone 11:15 11:35 a.m. Genomic Signatures Matthew Hellman 11:35 a.m. - noon Discussion Keith Kerr Noon 1:00 p.m. Lunch 1:00 2:30 p.m. Session IV: Immunotherapy 1 st Line Chairs: David Carbone, TBD 1:00 1:15 p.m. Pembolizumab, Single Agent Giorgio V. Scagliotti 1:15 1:30 p.m. Nivolumab, Single Agent David Carbone 1:30 1:45 p.m. Others Sanjay Popat 1:45 2:00 p.m. What is in the Horizon? TBD 2:00 2:30 p.m. Discussion Keunchil Park 2:30 4:15 p.m. Session V: Immunotherapy 2 nd Line Chairs: TBD, James Yang 2:30 2:45 p.m. No Previous IO James Yang 2:45 3:00 p.m. Previous IO Marina Garassino 3:00-3:15 p.m. Novel IO-Agents Enriqueta Felip 3:30 3:45 p.m. Master Protocols Vassiliki Papadimitrakopoulou 3:45 4:15 p.m. Discussion Thomas Newsom-Davis 4:15 4:30 p.m. Coffee Break 4:30 6:15 p.m. Session VI: Novel Combinations in Clinical Trials Chairs: Luis Paz-Ares, Tony Mok 4:50 5:05 p.m. IO + Chemotherapy Matthew Hellman 5:05 5:20 p.m. IO + Targeted Therapy Tetsuya Mitsudomi 5:20 5:35 p.m. TBD Vamsidhar Velcheti 5:35 6:00 p.m. Discussion Tony Mok

3 Friday, March 23, :00 7:00 p.m. Session VII: Vaccines Chairs: Johan Vansteenkiste, Glenn Goss 6:00 6:20 p.m. Overview Johan Vansteenkiste 6:20 6:40 p.m. Ongoing Clinical Trials Glenn Goss 6:40 7:00 p.m. Discussion Ross Soo 7:30 p.m. Faculty Dinner Saturday, March 24, :00 8:30 a.m. Registration and Breakfast 8:30 10:30 a.m. Session VIII: Clinical Management Chairs: Giorgio V. Scagliotti, TBD 8:30 8:45 a.m. Dosing Amount and Timing of Doses Fabrice Barlesi 8:45 9:00 a.m. Optimal Duration of Therapy TBD 9:00 9:15 a.m. Evaluation and Monitoring of Response Egbert Smit 9:15 9:30 a.m. Management of Side Effects Mariano Provencio 9:30 9:45 a.m. Post-PD Continuation of PD-L1/PD-1 Targeted Therapy David Planchard 9:45 10:00 a.m. Discussion Daniel Tan 10:00 11:45 a.m. Session IX: Stage III Disease Chairs: Everett Vokes, Rafal Dziadziuszko 10:00 10:20 a.m. Radiation and Immunotherapy Overview Umberto Ricardi 10:20 10:40 a.m. Clinical Impact of PACIFIC Luis Paz-Ares 10:40 11:00 a.m. Radiotherapy Perspectives Rafal Dziadziuszko 11:00 11:15 a.m. Other Studies Everett Vokes 11:15 11:45 a.m. Discussion Andrea Bezjak 11:45 a.m. 12:30 p.m. Lunch

4 Saturday, March 24, :30 1:30 p.m. Session X: Small Cell Lung Cancer and IO Chairs: Leora Horn, Caicun Zhou 12:30 12:50 p.m. Overview of Current Studies Leora Horn 12:50 1:10 p.m. Future Potential Studies and Study Design Patrick Ott 1:10 1:30 p.m. Discussion Caicun Zhou 1:30 3:00 p.m. Session XI: Mesothelioma Chairs: Dean Fennell, Anne Tsao 1:30 1:50 p.m. Overview of I/O and I/O+CTLA4 Studies Paul Baas 1:50 2:10 p.m. Early Stage I/O Trials and Combination I/O Trials with Anti-Angiogenics and Arginine Depleting Agents Anne Tsao 2:10 2:30 p.m. T-Cell Therapy Joachim Aerts 2:30 2:50 p.m. Mesothelin Targeted and Other Novel Agents Dean Fennell 2:50 3:00 p.m. Discussion Anne Tsao 3:00 4:30 p.m. Session XII: Early Stage NSCLC Chairs: Yi-long Wu, Suresh Ramalingam 3:00 3:30 p.m. Overview of Current Adjuvant Studies Suresh Ramalingam 3:30 3:45 p.m. Neo-adjuvant Studies Jay Lee 3:45 4:00 p.m. Neo-adjuvant Study Design and Endpoints Paul A. Bunn, Jr. 4:00 4:30 p.m. Discussion Yi-long Wu 4:30 5:00 p.m. Coffee Break 5:00 6:00 p.m. Session XIII: Immunoprevention Chairs: Ignacio Wistuba, Paul A. Bunn, Jr. 5:00 5:20 p.m. Immunobiology of Preneoplasia Ignacio Wistuba 5:20 5:40 p.m. Immunoprevention Trials Paul A. Bunn, Jr. 5:40 6:00 p.m. Discussion Myung-Ju Ahn 7:00 p.m. General Dinner

5 Sunday, March 25, :00 a.m. Noon Session XIV: Nurses Workshop Chairs: Kim Rohan, Marianne Davies 9:00 a.m. Noon Session XV: Advocate Workshop Chairs: Maureen Rigney, Csaba L. Dégi